U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C60H63N13O13S6
Molecular Weight 1366.612
Optical Activity UNSPECIFIED
Defined Stereocenters 6 / 6
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of LFF-571

SMILES

[H][C@](O)(C1=CC=CC=C1)[C@]2([H])NC(=O)CNC(=O)C3=C(COC)SC(=N3)[C@@H](NC(=O)C4=C(C)SC(=N4)[C@H](CC(=O)NC)NC(=O)C5=CSC(=N5)C6=C(N=C(C=C6)C7=NC(=CS7)N(CCCCC(O)=O)C(=O)O[C@H]8CC[C@@H](CC8)C(O)=O)C9=CSC(=N9)C%10=CSC2=N%10)C(C)C

InChI

InChIKey=GNLYKLDXQZHYTR-LMOGNUDZSA-N
InChI=1S/C60H63N13O13S6/c1-28(2)44-58-72-47(39(92-58)23-85-5)51(80)62-22-42(75)69-48(49(78)30-11-7-6-8-12-30)57-67-38(26-89-57)55-65-36(24-88-55)46-33(53-66-37(25-87-53)50(79)64-35(21-41(74)61-4)56-71-45(29(3)91-56)52(81)70-44)18-19-34(63-46)54-68-40(27-90-54)73(20-10-9-13-43(76)77)60(84)86-32-16-14-31(15-17-32)59(82)83/h6-8,11-12,18-19,24-28,31-32,35,44,48-49,78H,9-10,13-17,20-23H2,1-5H3,(H,61,74)(H,62,80)(H,64,79)(H,69,75)(H,70,81)(H,76,77)(H,82,83)/t31-,32-,35-,44-,48-,49-/m0/s1

HIDE SMILES / InChI
LFF-571 is a novel semisynthetic thiopeptide antibiotic with potent activity against a variety of Gram-positive pathogens, including Clostridium difficile. LFF-571 was generally safe and well tolerated in single and multiple oral doses in healthy subjects. There were no deaths, no serious adverse events, and no subject withdrawals due to an adverse event. The most common adverse event was diarrhea, gastrointestinal pain or distension was also noted. Similar to healthy volunteers, patients with C. difficile infections exhibited high fecal concentrations and low serum levels of LFF571. Novartis is developing oral LFF 571 for the treatment of Clostridium difficile infections. LFF 571 binds to bacterial elongation factor Tu (EF-Tu) in domain 2. Phase-II development is ongoing in USA and Canada.

Approval Year

PubMed

PubMed

TitleDatePubMed
Multicenter, randomized clinical trial to compare the safety and efficacy of LFF571 and vancomycin for Clostridium difficile infections.
2015 Mar
Pharmacokinetics of LFF571 and vancomycin in patients with moderate Clostridium difficile infections.
2015 Mar
Toxigenic Clostridium difficile PCR ribotypes in edible marine bivalve molluscs in Italy.
2015 Sep 2
New antibiotics in clinical trials for Clostridium difficile.
2016
Antibacterials Developed to Target a Single Organism: Mechanisms and Frequencies of Reduced Susceptibility to the Novel Anti-Clostridium difficile Compounds Fidaxomicin and LFF571.
2016 Feb 1
Novel antibiotics in development to treat Clostridium difficile infection.
2017 Jan
Elfamycins: inhibitors of elongation factor-Tu.
2017 Oct
Molecular typing and antimicrobial susceptibility testing to six antimicrobials of Clostridium difficile isolates from three Czech hospitals in Eastern Bohemia in 2011-2012.
2017 Sep
Novel Antimicrobials for the Treatment of Clostridium difficile Infection.
2018
Update of treatment algorithms for Clostridium difficile infection.
2018 May
Comparative efficacy of treatments for Clostridium difficile infection: a systematic review and network meta-analysis.
2018 Sep
Investigational drug therapies currently in early-stage clinical development for the treatment of clostridioides (clostridium) difficile infection.
2019 Apr

Sample Use Guides

200 mg four times daily for 10 days
Route of Administration: Oral
Name Type Language
LFF-571
Common Name English
(14S,21S,31S)-31-((S)-ALPHA-HYDROXYBENZYL)-14-(2-(METHYLAMINO)-2-OXOETHYL)-17-METHYL-21-ISOPROPYL-24-(METHOXYMETHYL)-4-(4-(((4BETA-CARBOXYCYCLOHEXANE-1ALPHA-YLOXY)CARBONYL)(4-CARBOXYBUTYL)AMINO)THIAZOLE-2-YL)9,16,23,33,37-PENTATHIA-3,13,20,27,30,39,40,41
Systematic Name English
J3.333.591A
Code English
LFF571
Code English
CYCLOHEXANECARBOXYLIC ACID, 4-((((4-CARBOXYBUTYL)(2-((11S,18S,28S)-10,11,17,18,23,24,25,26,27,28-DECAHYDRO-28-((S)-HYDROXYPHENYLMETHYL)-21-(METHOXYMETHYL)-14-METHYL-11-(2-(METHYLAMINO)-2-OXOETHYL)-18-(1-METHYLETHYL)-9,16,23,26-TETRAOXO-9H,16H-8,5:15,12:2
Systematic Name English
Code System Code Type Description
DRUG BANK
DB13013
Created by admin on Sat Dec 16 10:20:06 GMT 2023 , Edited by admin on Sat Dec 16 10:20:06 GMT 2023
PRIMARY
SMS_ID
300000041538
Created by admin on Sat Dec 16 10:20:06 GMT 2023 , Edited by admin on Sat Dec 16 10:20:06 GMT 2023
PRIMARY
FDA UNII
W7AUL2R95Z
Created by admin on Sat Dec 16 10:20:06 GMT 2023 , Edited by admin on Sat Dec 16 10:20:06 GMT 2023
PRIMARY
PUBCHEM
42638236
Created by admin on Sat Dec 16 10:20:06 GMT 2023 , Edited by admin on Sat Dec 16 10:20:06 GMT 2023
PRIMARY
CAS
1160959-55-6
Created by admin on Sat Dec 16 10:20:06 GMT 2023 , Edited by admin on Sat Dec 16 10:20:06 GMT 2023
PRIMARY